

United States District Court  
Northern District of California

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

IN THE UNITED STATES DISTRICT COURT  
FOR THE NORTHERN DISTRICT OF CALIFORNIA

CITY AND COUNTY OF SAN  
FRANCISCO, et al.,

Plaintiffs,

v.

PURDUE PHARMA L.P., et al.,

Defendants.

Case No. 18-cv-07591-CRB

**ORDER GRANTING IN PART AND  
DENYING IN PART PLAINTIFF’S  
MOTION FOR SUMMARY  
JUDGMENT ON DEFENDANTS’  
AFFIRMATIVE DEFENSES**

Re: Dkt. No. 973

Defendants collectively assert 390 affirmative defenses for which they will bear the burden of proof at trial. See MSJ (dkt. 973) at 3 (citing Ex. A (dkt. 973–1)). Plaintiff argues that it is entitled to judgment on the pleadings or, in the alternative, to summary judgment on all 390 affirmative defenses because there is “an absence of evidence as to all of Defendants’ affirmative defenses because they are too vague, conclusory, and factually unsupported to raise genuine disputes of material fact.” MSJ at 3. For the reasons discussed below, the motion is granted in part and denied in part.

**I. DISCUSSION**

Plaintiff asserts UCL and public nuisance claims against Defendants. The UCL claim seeks civil penalties and injunctive relief, and the public nuisance claim seeks an abatement fund to redress prospective harm expected to occur because of the ongoing opioid epidemic in San Francisco. See MSJ at 1. Plaintiff does not seek “damages or recovery of historical costs” or “restitution as remedy.” Id.

Plaintiff broadly argues that “Defendants assert boilerplate affirmative defenses that

1 are without factual support or that are denials of Plaintiff’s prima facie case and are not  
 2 actual affirmative defenses.” See MSJ at 4. The argument targets all 390 of the affirmative  
 3 defenses collectively asserted by Defendants. But Plaintiff identifies only a handful of the  
 4 defenses that it contends are insufficiently pled, factually unsupported, or otherwise fail as  
 5 a matter of law. See generally id. In other words, Plaintiff’s motion does not specifically  
 6 address many of the 390 defenses for which it contends that it is entitled to judgment on  
 7 the pleadings or summary judgment.

8 Defendants argue that Plaintiff is not entitled to summary judgment or judgment on  
 9 the pleadings for any defense that is not specifically challenged. See Opp. at 4–5. The  
 10 Court agrees. To the extent that Plaintiff does not make specific arguments about a certain  
 11 defenses or category of defenses—which is the case for many of the 390 defenses that  
 12 Plaintiff purports to challenge—the Court denies Plaintiff’s motion. The Court considers  
 13 each of Plaintiff’s arguments regarding specific defenses and categories of defenses  
 14 below.<sup>1</sup>

#### 15 **A. Blanket Defenses**

16 Defendants allege what Plaintiff characterizes as several broad “catchall” defenses.  
 17 See MSJ at 5 (citing Endo Answ. at 167; Par Answ. at 135; Walgreens Answ. at 151; Teva  
 18 Answ. at 144; Cephalon Answ. at 144). Defendants do not oppose Plaintiff’s motion as to  
 19 these defenses. Thus, summary judgment is granted for these defenses.

#### 20 **B. Inapplicable Defenses**

21 Plaintiff argues that the following defenses “have no conceivable applicability” to  
 22 the public nuisance and UCL claims. MSJ at 5.

- 23 • Voluntary payment doctrine (Walgreens Answ. at 151; Teva Answ. at 138;  
 24 Cephalon Answ. at 138; Endo Answ. at 172; Par Answ. at 139; Actavis Answ. at

25  
 26 <sup>1</sup> The parties dispute whether Plaintiff’s motion for judgment on the pleadings is procedurally  
 27 proper to the extent that it seeks judgment on the pleadings for defenses that are insufficiently  
 28 pled. See Opp. at 5–7 (“Once the deadline for filing a motion to strike has passed, any non-  
 29 evidence-based challenge to an affirmative defense must be limited to its ‘legal’ viability.”); see  
 30 also Reply at 3–6. Because the Court’s rulings are based on Rule 56, the Court does not reach this

1 160)

- 2 • Products liability defenses (Anda Answ. at 119; Allergan Answ. at 134;  
3 Walgreens Answ. at 158)
- 4 • Subrogation and insurance defenses (Anda Answ. at 122; Allergan Answ. at  
5 136; Par Answ. at 143; Walgreens Answ. at 152)
- 6 • Workers' compensation claims (Anda Answ. at 122; Allergan Answ. at 137;  
7 Walgreens Answ. at 153)

8 Each defense is considered in turn.

9 **1. Voluntary Payment Doctrine**

10 The “voluntary payment doctrine” is based on the principle that “a payment  
11 voluntarily made with knowledge of the facts affords no ground for an action to recover it  
12 back.” Am. Oil Serv. v. Hope Oil Co., 15 Cal. Rptr. 209, 213 (Ct. App. 1961); see also W.  
13 Gulf Oil Co. v. Title Ins. & Tr. Co., 92 Cal. App. 2d 257, 265, 206 P.2d 643, 648 (1949)  
14 (“Payments voluntarily made, with knowledge of the facts, cannot be recovered.”).

15 Plaintiff argues that the doctrine does not apply here because the “nuisance and  
16 UCL claims do not seek to recover any payments made.” See MSJ at 5. Plaintiff has  
17 dropped its claim for restitution, and the only monetary relief that Plaintiff seeks is civil  
18 penalties and a forward-looking abatement fund. Id.

19 Defendants respond that even though Plaintiff does not seek money damages, the  
20 voluntary payment doctrine should still apply because Plaintiff’s request for an abatement  
21 fund “is really just a request for a huge pot of money” to cover costs Plaintiff expects to  
22 incur in coming years to redress opioid-related harms. Opp. at 11.

23 Defendants cite no authority to support their argument that the voluntary payment  
24 doctrine applies to a prospective abatement fund. Nor do Defendants otherwise show why  
25 the doctrine should apply to Plaintiff’s claims for civil penalties and abatement. Thus,  
26 summary judgment on the voluntary payment defense is granted.

27 **2. Products Liability Defenses**

28 In its opening brief, Plaintiff asserts that Defendants’ strict products liability

1 defense has “no conceivable applicability” to the nuisance and UCL claims because the  
2 defense applies only to products liability actions. MSJ at 5. Although they recognize that  
3 Plaintiff is not asserting a products liability action, Defendants contend that Plaintiff is  
4 effectively pursuing a products liability action “in the guise of a nuisance action.” Opp. at  
5 12.

6 Defendants’ argument is not persuasive. The “telltale sign” of a products liability  
7 action is that the plaintiff is “seeking to hold the defendant liable precisely because the  
8 product’s potential for harm substantially outweighs any possible benefit derived from it.”  
9 Opp. at 12 (citing Merrill v. Navegar, Inc., 26 Cal. 4th 465, 478 (2001) (cleaned up)). But  
10 here, Plaintiff’s theories of liability are that (1) Defendants made false and misleading  
11 statements about the safety and efficacy of opioids and (2) Defendants failed to implement  
12 effective systems to monitor for suspicious orders of opioids and to prevent diversion of  
13 opioids. Neither theory alleges that the potential for harm from opioids substantially  
14 outweighs their benefits—rather, the theories are based on alleged misrepresentations and  
15 systemic failures to monitor for diversion. Thus, summary judgment is granted as to the  
16 products liability defenses.

### 17 3. Subrogation

18 Plaintiff argues that Defendants’ defense of subrogation is only relevant to insurers’  
19 claims. See MTD at 5–6. Defendants respond that subrogation claims may arise here  
20 because Plaintiff’s claims are based on the theory that “Defendants’ alleged wrongful  
21 conduct resulted in personal injury and death to individuals.” Opp. at 13. But Defendants  
22 do not identify any specific subrogation interests at issue, nor do Defendants identify any  
23 person who may hold a subrogation interest. Accordingly, summary judgment is granted  
24 as to the subrogation defenses.

### 25 4. Remoteness and Derivative Injury

26 Plaintiffs argue that the defenses of remoteness and derivative injury are limited to  
27 workers compensation cases. MSJ at 5. In their opposition, Defendants appear to argue  
28 that the defenses apply here because Plaintiff “must prove proximate causation and a

1 defendant may not be held liable if the alleged misconduct is ‘too remote’ to be a ‘legally  
 2 sufficient proximate cause.’ Opp. at 13–14. But Defendants’ arguments attack Plaintiff’s  
 3 ability to carry its burden of proving the elements of its claims. Defendants do not show  
 4 why the affirmative defenses of remoteness and derivative injury apply here. Accordingly,  
 5 summary judgment is granted with respect to these defenses.

### 6 C. Factually Unsupported Defenses

7 In its opening brief, Plaintiff argues that certain defenses are “boilerplate defenses”  
 8 pled without factual support. MSJ at 4-5. Plaintiff specifically points to the following:

- 9 • Actavis, Cephalon, and Teva’s defenses asserting doctrines of laches, waiver,  
 10 unclean hands, estoppel, release, and/or ratification (“equitable defenses”)
- 11 • Anda’s defense asserting that Plaintiff’s action is “arbitrary and capricious”
- 12 • Endo and Par’s affirmative defenses asserting the statute of limitations

13 In its reply brief, Plaintiff concedes that Defendants’ statute of limitations defense is  
 14 viable. See Reply at 1 (“Defendants fail to show triable issues on any but the UCL statute  
 15 of limitations.”). And Defendants do not oppose Plaintiff’s motion as to the “arbitrary and  
 16 capricious” defense. See generally Opp. Thus, the motion is denied as to the statute of  
 17 limitations defenses and granted as to the “arbitrary and capricious” defenses.

18 As to the equitable defenses, Defendants argue that they are entitled to assert the  
 19 equitable defenses because Plaintiff is “seeking equitable remedies” and “California law  
 20 permits equitable defenses to be asserted against a government entity seeking such relief.”  
 21 See Opp. at 9. Defendants also cite evidence supporting the defenses, including evidence  
 22 suggesting that Plaintiff delayed in filing their claims. Opp. at 10.

23 In ConAgra, the California Court of Appeals held that ““neither the doctrine of  
 24 estoppel nor any other equitable principle may be invoked against a governmental body  
 25 where it would operate to defeat the effective operation of a policy adopted to protect the  
 26 public.”” 17 Cal. App. 5th 51, 136 (quoting County of San Diego v. California Water &  
 27 Tel. Co., 30 Cal. 2d 817, 826 (1947)). There, the court rejected defendant’s assertion of

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.